US4356190A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibiting production of undesirable products on body surfaces and environs employing aminopolycarboxylic compounds
Assignee: Personal Products Co
•
Filing: 1978-10-16
•
Granted: 1982-10-26
•
Expires: 1998-10-16
Abstract
Abstract Methods, compositions and products are described which inhibit formation of undesirable products on body surfaces and environs resulting from microbial action on lipoidal materials in body secretions. Amino acid compounds are employed.
Inventors
- 👤 Kenneth S. Kraskin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 05:42
CPC Classifications
A; A61; A61Q; A61Q15/00; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/40; A61K8/44; A61L; A61L15/00; A61L15/16; A61L15/42; A61L15/46; A61L2300/00; A61L2300/20; A61L2300/21; A61L2300/40; A61L2300/404
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
123 words
A method of inhibiting the formation of fatty acids having from 4 to 18 carbon atoms per molecule from the degradation of skin secretions by Corynebacterium comprising applying to the skin, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, an aminopolycarboxylic compound selected from the group consisting of ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, N-hydroxyethylethylenediaminetriaacetic acid, triethylenetetraaminehexaacetic acid, 1,2-diaminocyclohexane-N,N'-tetraacetic acid, N,N-dihydroxyethylethylenediaminediacetic acid, iminodiacetic acid, hydroxyethyliminodiacetic acid, nitrilotriacetic acid and their water soluble salts; said aminopolycarboxylic compound being present in a concentration of 0.5 to 10 weight percent in said composition, based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 2
Independent Claim
123 words
A method of inhibiting the formation of fatty acids having from 4 to 18 carbon atoms per molecule from the degradation of skin secretions by Corynebacterium comprising applying to the skin, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, an aminopolycarboxylic compound selected from the group consisting of ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, N-hydroxyethylethylenediaminetriaacetic acid, triethylenetetraaminehexaacetic acid, 1,2-diaminocyclohexane-N,N'-tetraacetic acid, N,N-dihydroxyethylethylenediaminediacetic acid, iminodiacetic acid, hydroxyethyliminodiacetic acid, nitrilotriacetic acid and their water soluble salts; said aminopolycarboxylic compound being present in a concentration of 0.5 to 10 weight percent in said composition, based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 3
Independent Claim
95 words
A method of inhibiting the formation of fatty acids having from 4 to 18 carbon atoms per molecule from the degradation of skin secretions by Corynebacterium comprising applying to the skin, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of 0.5 to 10 weight percent of said acid in said composition based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 4
Independent Claim
95 words
A method of inhibiting the formation of fatty acids having from 4 to 18 carbon atoms per molecule from the degradation of skin secretions by Corynebacterium comprising applying to the skin, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of 0.5 to 10 weight percent of said acid in said composition based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 5
Dependent Claim
14 words
The method of claim 2 wherein said water-soluble salt is an alkali metal salt.
Claim 6
Dependent Claim
13 words
The method of claim 3 wherein said water-soluble salt is a sodium salt.
Claim 7
Dependent Claim
12 words
The method of claim 4 wherein said water-soluble salt is disodium-ethylenediaminetetraacetic acid.
Claim 8
Dependent Claim
12 words
The method of claim 4 wherein said water-soluble salt is trisodium-ethylenediaminetetraacetic acid.
Claim 9
Dependent Claim
12 words
The method of claim 4 wherein said water-soluble salt is tetrasodium-ethylenediaminetetraacetic acid.
Claim 10
Dependent Claim
17 words
The method of claim 4 wherein said water-soluble salt is a mixture of disodium and tetrasodium-ethylenediaminetetraacetic acid.
Claim 11
Dependent Claim
14 words
The method of claim 2 wherein said water-soluble salt is a lower alkanolamine salt.
Claim 12
Dependent Claim
16 words
The method of claim 2 wherein said water-soluble salt is the trialkanolamine salt of ethylenediaminetetraacetic acid.
Claim 13
Independent Claim
95 words
A method of inhibiting the formation of lower fatty acids from the degradation of skin secretions in the axillary area by Corynebacterium comprising applying to the skin in the axillary area, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of 0.5 to 10 weight percent of said acid in said composition based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 14
Independent Claim
95 words
A method of inhibiting the formation of lower fatty acids from the degradation of skin secretions in the axillary area by Corynebacterium comprising applying to the skin in the axillary area, in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of 0.5 to 10 weight percent of said acid in said composition based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 15
Dependent Claim
20 words
The method of claim 11 wherein said lower fatty acids comprise fatty acids having no more than five carbon atoms.
Claim 16
Dependent Claim
14 words
The method of claim 12 wherein said water-soluble salt is an alkali metal salt.
Claim 17
Dependent Claim
13 words
The method of claim 13 wherein said water-soluble said is a sodium salt.
Claim 18
Dependent Claim
12 words
The method of claim 14 wherein said water-soluble salt is disodium-ethylenediaminetetraacetic acid.
Claim 19
Dependent Claim
12 words
The method of claim 14 wherein said water-soluble salt is trisodium-ethylenediaminetetraacetic acid.
Claim 20
Dependent Claim
12 words
The method of claim 14 wherein said water-soluble salt is tetrasodium-ethylenediaminetetraacetic acid.
Claim 21
Dependent Claim
17 words
The method of claim 14 wherein said water-soluble salt is a mixture of disodium and tetrasodium-ethylenediaminetetraacetic acid.
Claim 22
Dependent Claim
14 words
The method of claim 12 wherein said water-soluble salt is a lower alkanolamine salt.
Claim 23
Dependent Claim
16 words
The method of claim 12 wherein said water-soluble salt is the trialkanolamine salt of ethylenediaminetetraacetic acid.
Claim 24
Independent Claim
99 words
A method of treating inflammatory skin conditions comprising inhibiting the formation of fatty acids of up to about 18 carbon atoms from the degradation of skin secretions by Corynebacterium comprising applying to the skin in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of from 2 to 15% by weight of said acid in said composition, based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 25
Independent Claim
99 words
A method of treating inflammatory skin conditions comprising inhibiting the formation of fatty acids of up to about 18 carbon atoms from the degradation of skin secretions by Corynebacterium comprising applying to the skin in an amount effective to inhibit the formation of said fatty acids, a composition comprising a carrier suitable for topical application and, as the sole essential ingredient, a water-soluble salt of ethylenediaminetetraacetic acid in a concentration of from 2 to 15% by weight of said acid in said composition, based on the weight of the free acid, said composition maintaining the viability of said Corynebacterium.
Claim 26
Dependent Claim
14 words
The method of claim 21 wherein said water-soluble salt is an alkali metal salt.
Claim 27
Dependent Claim
13 words
The method of claim 22 wherein said water-soluble salt is a sodium salt.
Claim 28
Dependent Claim
12 words
The method of claim 23 wherein said water-soluble salt is disodium-ethylenediaminetetraacetic acid.
Claim 29
Dependent Claim
12 words
The method of claim 23 wherein said water-soluble salt is trisodium-ethylenediaminetetraacetic acid.
Claim 30
Dependent Claim
12 words
The method of claim 23 wherein said water-soluble salt is tetrasodium-ethylenediaminetetraacetic acid.
Claim 31
Dependent Claim
17 words
The method of claim 23 wherein said water-soluble salt is a mixture of disodium and tetrasodium-ethylenediaminetetraacetic acid.
Claim 32
Dependent Claim
14 words
The method of claim 21 wherein said water-soluble salt is a lower alkanolamine salt.
Claim 33
Dependent Claim
16 words
The method of claim 21 wherein said water-soluble salt is the trialkanolamine salt of ethylenediaminetetraacetic acid.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-10-25 | 1986-04-26 | 1986-10-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-10-25 | 1990-04-26 | 1990-10-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-10-25 | 1994-04-26 | 1994-10-26 | $7700.00 | Window Closed / Lapsed |